S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96

Arrowhead Pharmaceuticals Stock Forecast, Price & News

+3.20 (+8.90%)
(As of 07/5/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
926,416 shs
Average Volume
893,716 shs
Market Capitalization
$4.14 billion
P/E Ratio
Dividend Yield
Price Target

Arrowhead Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
86.4% Upside
$73.00 Price Target
Short Interest
6.10% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.28mentions of Arrowhead Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.03) to ($1.65) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.95 out of 5 stars

Medical Sector

567th out of 1,426 stocks

Pharmaceutical Preparations Industry

271st out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Arrowhead Pharmaceuticals logo

About Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

ARWR Stock News Headlines

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 3.4%
5 Top Biotech Stocks To Watch In July 2022
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$138.29 million
Book Value
$3.92 per share


Free Float
Market Cap
$4.14 billion

Arrowhead Pharmaceuticals Frequently Asked Questions

Should I buy or sell Arrowhead Pharmaceuticals stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arrowhead Pharmaceuticals stock.
View analyst ratings for Arrowhead Pharmaceuticals
or view top-rated stocks.

What is Arrowhead Pharmaceuticals' stock price forecast for 2022?

6 brokerages have issued 1 year price targets for Arrowhead Pharmaceuticals' shares. Their ARWR stock forecasts range from $36.00 to $110.00. On average, they expect Arrowhead Pharmaceuticals' share price to reach $73.00 in the next twelve months. This suggests a possible upside of 86.4% from the stock's current price.
View analysts' price targets for Arrowhead Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Arrowhead Pharmaceuticals' stock performed in 2022?

Arrowhead Pharmaceuticals' stock was trading at $66.30 on January 1st, 2022. Since then, ARWR shares have decreased by 40.9% and is now trading at $39.16.
View the best growth stocks for 2022 here

When is Arrowhead Pharmaceuticals' next earnings date?

Arrowhead Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Arrowhead Pharmaceuticals

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released its quarterly earnings results on Tuesday, May, 10th. The biotechnology company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.39 by $0.02. The biotechnology company earned $151.80 million during the quarter, compared to analysts' expectations of $122.15 million. Arrowhead Pharmaceuticals had a negative trailing twelve-month return on equity of 26.77% and a negative net margin of 42.44%. The firm's revenue was up 362.8% compared to the same quarter last year. During the same period last year, the firm earned ($0.26) EPS.
View Arrowhead Pharmaceuticals' earnings history

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the following people:
  • Dr. Christopher R. Anzalone Ph.D., CEO, Pres & Director (Age 53, Pay $1.68M)
  • Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 56, Pay $729.77k) (LinkedIn Profile)
  • Mr. Patrick O'Brien, Chief Compliance Officer, Gen. Counsel & Corp. Sec. (Age 58, Pay $733.13k)
  • Dr. James C. Hamilton M.D., MBA, Sr. VP of Discovery & Translational Medicine (Age 43, Pay $673.45k)
  • Dr. Javier San Martin M.D., Chief Medical Officer (Age 57, Pay $658.48k)
  • Dr. Mark M. Davis Ph.D., Founder and Founder & Director of Insert Therapeutics Inc & Calando
  • Ms. Jane Davidson, Head of HR & Admin., VP and Corp. Sec.
  • Dr. Vincent Anzalone CFA, Head of Investor Relations & VP
  • Mr. Howard Lovy, Director of Communications
  • Dr. Mark Seefeld, Head of Toxicology & VP (Age 68)

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD).

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $39.16.

How much money does Arrowhead Pharmaceuticals make?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a market capitalization of $4.14 billion and generates $138.29 million in revenue each year. The biotechnology company earns $-140,850,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis.

How many employees does Arrowhead Pharmaceuticals have?

Arrowhead Pharmaceuticals employs 329 workers across the globe.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The official website for Arrowhead Pharmaceuticals is www.arrowheadpharma.com. The biotechnology company can be reached via phone at (626) 304-3400, via email at ir@arrowheadpharma.com, or via fax at 626-304-3401.

This page (NASDAQ:ARWR) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.